Healthwell Acquisition Corp. I (Nasdaq: HWEL) announced on Friday evening that its former target Starton has terminated its business combination.
Although the parties did not provide extensive detail regarding the termination, they clarified that the deal fell through due to certain closing conditions not being satisfied by the outside date of November 3.
Healthwell I unveiled its $339 million combination with Starton earlier this year in April. While the two sides initially agreed on a $15 million closing condition, they later reduced this to $10 million in September.
The SPAC brought about $253.7 million into the deal through its trust, but following redemptions from previous votes, it was left with around $41.8 million. Despite the expectation of supplementing this with $15 million from a PIPE or a debt facility, there has been no confirmation of securing this funding.
Paramus, New Jersey-based Starton is developing a line of treatments to improve efficacies in delivering drugs for certain types of cancer and mitigating the side effects of chemotherapy. Going forward, Starton will continue its clinical efforts to meet the completion of its study for the advancement of its patients.
As a result of this termination, Healthwell I will seek an alternative business combination. With a completion deadline of December 5, it currently has just a month to find a suitable target to combine with. However, it recently filed a proxy to hold a shareholder meeting aimed at extending this deadline until August 2024, granting them a nine-month window to finalize a deal.
At the SPAC of Dawn Tuesday brings a big day of US retail sales readings, which generally get outsized attention in the thick of the holiday season. A pair of US retail sales indicators are set to report at 8:30 am ET, while industrial production figures and capacity utilization are set for a 9:15 am...
Jackson Acquisition Company II (NYSE:JACS.U) announced the pricing of its $200 million IPO and its units are expected to begin trading on the NYSE under the symbol “JACS.U”, Tuesday, December 10 2024. The new SPAC intends to search for a healthcare target that can benefit from its team’s relationships within the healthcare services space nationally....
SPAC deal flow has hit a slump in the second half of 2024 as the SPAC ecosystem transitions from one generation of SPACs to another. This year started with 128 SPACs still searching for a target and 102 SPACs are still in that state today. So, one might expect a more vigorous pace of announced...
At the SPAC of Dawn The second week of December kicks off with plenty of business on the schedule. Eight SPACs are holding votes of some kind while both Swiftmerge (NASDAQ:IVCP) and Mars (NASDAQ:MARX) ask their shareholders for approval of their deals. Swiftmerge has been working to take natural gas producer AleAnna public since June...
Terms Tracker for the Week Ending December 6, 2024 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. SPACs managed two IPO pricings this week bringing the 2024 YTD count to 52. However, earlier in the week it was expected that four SPAC...